Are you a pulmonary/respiratory specialist practicing in the United States? * Yes No How many patients with idiopathic pulmonary fibrosis (IPF) do you see per month (on average) * Less than 5 6 – 10 More than 10 Of your patients with an IPF diagnosis, how many are being treated with pirfenidone? * None Less than 25% 26% - 50% 51% - 75% More than 75% Of your patients with an IPF diagnosis, how many are being treated with nintedanib? * None Less than 25% 26% - 50% 51% - 75% More than 75% Of your patients with an IPF diagnosis, how many are being treated with prednisone, azathioprine and NAC combination therapy? * None Less than 25% 26% - 50% 51% - 75% More than 75% Of your patients with an IPF diagnosis, how many are being treated with a PPI? * None Less than 25% 26% - 50% 51% - 75% More than 75% Of your patients with an IPF diagnosis, how many have undergone genetic testing (either TOLLIP or MUC5B)? * None Less than 25% 26% - 50% 51% - 75% More than 75% Please rate your degree of familiarity with molecular biomarkers for prediction of IPF prognosis: * Not at all familiar Somewhat familiar Very familiar Extremely familiar Please rate your degree of familiarity with the 2015 ATS/ERS/JRS/ALSAT guidelines for the treatment of IPF: * Not at all familiar Somewhat familiar Very familiar Extremely familiar For your patients receiving pirfendone or ninetanib, which of the following led to your decision? * Current guideline recommendations Evidence from clinical trials supporting their use in IPF Patient request Available reimbursement For your patients on agents other than pirfendone or ninetanib, which of the following led to your decision? * Disagree with or not aware of current guideline recommendations Unaware of data supporting their use in IPF Patient refusal Cost Leave this field blank
